Genetic Developmental and Epileptic Encephalopathy Natural History Study for Clinical Trial Readiness

ConditionsMEF2CDEE
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorWeill Medical College of Cornell University

About this trial

Phase 0 non-interventional longitudinal study of children and adults with Developmental and Epileptic Encephalopathy (DEE) due to a genetic cause. There are six arms of the study. Arms 1, 2, and 3 are devoted to one example DEE, MEF2C Haploinsufficiency Syndrome (MCHS). Arms 4, 5, and 6 are open to all DEE. Arm 1 (in-person) will enroll children 0 to 15, who will make in-person visits to Weill Cornell Medicine four times over two years. Arm 2 (virtual) will enroll people of all ages and older who will make virtual visits over Weill Cornell Zoom to Weill Cornell Medicine over two years (2 if 16 and older; 4 if 0 to 15). Arm 3 (registry) will enroll people of all ages in an online-only survey. Arms 4 - 6 mirror this structure but they are open to all children with DEE. Arm 4 (in-person) will enroll children of any age, who will make in-person visits every 6 months for 10 years. Arm 5 (virtual) will enroll children of any age for virtual visits, twice a year of 0 to 15, once a year if 16 or older. Arm 6 (registry) will enroll people of all ages in an online only survey.

Eligibility criteria

Qualifiers

Molecular diagnosis of a genetic disorder associated with DEE, as confirmed by the study investigators

A neurological phenotype such as epilepsy or developmental delay as confirmed by the study investigators.

English Speaking (Arms 1, 2, 4, 5). The registries may be completed by people who speak any language.

MEF2C

Disqualifiers

Presence of a significant non-DEE-related central nervous impairment/behavioral disturbance that would confound the scientific rigor or interpretation of results of the study

History of prematurity (defined as gestational age <35 weeks), interventricular hemorrhage, structural brain deficit, or congenital heart disease

Presence of a clinical comorbidity deemed by the investigator to potentially confound the typical presentation of DEE

Trial design

Treatments tested in this trial

  • Observation

Treatment groups

22,068 Participants
are divided into 6 treatment groups

6

Treatment groups

See each treatment group below.

Sponsors and collaborators